The American Society of Colon and Rectal Surgeons Clinical Practice

Total Page:16

File Type:pdf, Size:1020Kb

The American Society of Colon and Rectal Surgeons Clinical Practice CLINICAL PRACTICE GUIDELINES 05/18/2021 on m7j+Lz0A3Xux7u8LH54Mj5YEKJ1nYV8VK4orUjhbpk89GhwzOnar+8anRBK3LfF1V2zEXE1u0nGxPGdFl1M3hEeUEtFEphcxy9cz7yeir/pEV8b5POc6vbIuuK2BN7bKd/4WfXOBO9Zdt9xCqbLQaKAuqUBNPYvKIxVC/YioDhw= by http://journals.lww.com/dcrjournal from Downloaded The American Society of Colon and Rectal Surgeons Downloaded Clinical Practice Guidelines for the Management of from http://journals.lww.com/dcrjournal Clostridioides difficile Infection Vitaliy Poylin, M.D.1 • Alexander T. Hawkins, M.D., M.P.H.2 • Anuradha R. Bhama, M.D.3 Marylise Boutros, M.D.4 • Amy L. Lightner, M.D.5 • Sahil Khanna, M.B.B.S., M.S.6 Ian M. Paquette, M.D.7 • Daniel L. Feingold, M.D.8 by m7j+Lz0A3Xux7u8LH54Mj5YEKJ1nYV8VK4orUjhbpk89GhwzOnar+8anRBK3LfF1V2zEXE1u0nGxPGdFl1M3hEeUEtFEphcxy9cz7yeir/pEV8b5POc6vbIuuK2BN7bKd/4WfXOBO9Zdt9xCqbLQaKAuqUBNPYvKIxVC/YioDhw= Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons 1 Division of Gastrointestinal Surgery, Northwestern Medicine, Chicago, Illinois 2 Department of Surgery, Section of Colon & Rectal Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 3 Department of Surgery, Division of Colon & Rectal Surgery, Rush University Medical Center, Chicago, Illinois 4 Jewish General Hospital, McGill University, Montreal, Quebec, Canada 5 Department of Colorectal Surgery, Digestive Disease Surgery Institute, Cleveland Clinic, Cleveland, Ohio 6 Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 7 Department of Surgery, University of Cincinnati, Cincinnati, Ohio 8 Section of Colorectal Surgery, Rutgers University, New Brunswick, New Jersey he American Society of Colon and Rectal These guidelines should not be deemed inclusive of all Surgeons (ASCRS) is dedicated to ensuring high- proper methods of care nor exclusive of methods of care quality patient care by advancing the science, reasonably directed toward obtaining the same results. Tprevention, and management of disorders and diseases The ultimate judgment regarding the propriety of any spe- of the colon, rectum, and anus. The Clinical Practice cific procedure must be made by the physician considering Guidelines Committee is composed of society members all the circumstances presented by the individual patient. who are chosen because they have demonstrated exper- tise in the specialty of colon and rectal surgery. This STATEMENT OF THE PROBLEM committee was created to lead international efforts in defining quality care for conditions related to the colon, Clostridioides difficile, formerly known as Clostridium dif- rectum, and anus and develop clinical practice guide- ficile, is an anaerobic, gram-positive, bacillus bacterium lines based on the best available evidence. Although not that can be a normal inhabitant of the human colon and proscriptive, these guidelines provide information on is most commonly transmitted via a fecal-oral route.1 which decisions can be made and do not dictate a spe- Alterations in the bacterial component of the microbiota, cific form of treatment. These guidelines are intended most often due to the use of antibiotics, can lead to eco- for the use of all practitioners, health care workers, and logical changes that select for both population growth of C patients who desire information about the management difficile as well as the induction of pathogenic behavior.2,3 of the conditions addressed by the topics covered in Although the number of patients with C difficile infection these guidelines. (CDI) in the United States appears relatively stable over the past decade (estimated 476,400 cases in 2011 associ- ated with 29,000 deaths and 462,100 cases in 2017 associ- Funding/Support: None reported. on ated with an estimated 20,500 deaths), the prevalence of 05/18/2021 3–5 Financial Disclosures: None reported. the disease remains high. Although the bacterium is present in the stool of approximately 3% of healthy adults, Correspondence: Daniel L. Feingold, M.D., Professor and Chair, up to 50% of those exposed to an inpatient facility may be Section of Colorectal Surgery, Rutgers University, 125 Patterson St, New asymptomatic carriers.5–8 Higher rates of CDI have been Brunswick, NJ 08901. E-mail: [email protected]. reported in patients after exposure to a prolonged dura- Dis Colon Rectum 2021; 64: 650–668 tion of antibiotics including perioperative antibiotics and DOI: 10.1097/DCR.0000000000002047 in patients with underlying comorbid conditions such as © The ASCRS 2021 IBD or immunosuppression.9–15 650 DISEASES OF THE COLON & RECTUM VOLUME 64: 6 (2021) Copyright © The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited. DISEASES OF THE COLON & RECTUM VOLUME 64: 6 (2021) 651 TABLE 1. Terminology associated with Clostridioides difficile Term Definition Antibiotic-associated diarrhea Diarrhea in an individual who is currently taking or has recently taken antibiotics (not necessarily from C difficile, although C difficile is a cause of this type of diarrhea) Symptoms include watery diarrhea and abdominal cramping Asymptomatic colonization/carrier Patients colonized with C difficile without signs or symptoms of CDI C difficile infection (CDI) Presence of diarrhea characterized by >3 watery stools per day in the setting of positive C difficile testing Other symptoms can include fever, abdominal pain, cramping, nausea, and loss of appetite Higher-risk patients include elderly or immunocompromised patients, nursing home residents, and patients with severe underlying comorbidities who have been exposed to antibiotics Pseudomembranous colitis Presence of plaque formations on colon mucosa Considered pathognomonic for CDI in the appropriate clinical setting Mild/nonsevere infection CDI with leukocyte count <15 × 103/µL and creatinine <1.5 mg/dL Severe infection CDI with leukocyte count >15 × 103/µL or renal failure with creatinine >1.5 mg/dL Severe-complicated/fulminant disease CDI with hypotension, sepsis, shock, ileus, or megacolon or requiring intensive care unit care Toxic colitis CDI with extreme inflammation and dilation of the colon resulting from severe colitis Can present with abdominal distension and pain, fever, dehydration, sepsis Recurrent CDI Recurrence of symptoms with a positive stool test within 8 weeks after the completion of a course of CDI therapy with resolution of symptoms Refractory CDI More than 3 loose/watery stools per day with positive stool toxin assay despite appropriate therapy CDI = Clostridioides difficile infection. Clinical manifestations of C difficile can range from METHODOLOGY an asymptomatic carrier state to mild CDI to severe, fulminant, life-threatening infection. Although descrip- These guidelines were developed on the platform of the pre- viously published Practice Parameters for the Management tions of presentation and severity of disease vary in 42 the literature, commonly used definitions are included of Clostridium difficile Infection published in 2015. An in Table 1.16–19 C difficile infection most commonly organized, systematic search of MEDLINE, PubMed, involves the colon, where it can manifest with pseudo- EMBASE, Web of Science, and the Cochrane Database membranes covering the colonic mucosa (“pseudomem- of Collected Reviews was performed between September branous colitis”). In rare circumstances, CDI may also 1, 2014 and September 20, 2020. Key word combina- involve the small bowel.20,21 In the early 2000s, predomi- tions included “Clostridium difficile,” “Clostridioides dif- nantly in North America, but also in Europe, there was ficile,” “Clostridia,” “colitis,” “pseudomembranous colitis,” an increased incidence of more severe CDI due to the “antibiotic-associated,” “diarrhea,” “cdiff,” “vancomycin,” emergence of certain bacterial strains (ie, ribotypes) like “flagyl,” “metronidazole,” “rifaximin,” “antibiotics,” “col- the BI/NAP1/027/toxinotype III strain, which is associ- ectomy,” “ileostomy,” “lavage,” “toxin,” “toxin binding,” ated with a life-threatening infection.22–25 Although rates “fecal transplant,” “probiotics,” “transmission,” “recur- of infection with this “hypervirulent” strain recently rence,” “recalcitrant,” “treatment,” “length of therapy,” decreased in North America, rates remain significant “perforation,” “fulminant,” “prophylaxis,” “prevention,” globally.26,27 and “megacolon.” Although the search was not limited A variety of practice measures and collaborative by language, only abstracts and reports with human sub- efforts have been implemented to reduce the rate of CDI jects were included. Emphasis was placed on prospective and have had moderate success.18,19,28–32 The combination trials, meta-analyses, systematic reviews, and practice of antibiotic stewardship programs and improved diag- guidelines. Peer-reviewed observational studies and ret- nosis and treatment have decreased the incidence and rospective studies were included when higher-quality mortality rates of CDI; however, CDI continues to be a evidence was insufficient. Directed searches using embed- source of morbidity and mortality due in part to a rise in ded references from primary articles were performed in recurrent and resistant infections.33–37 The relatively high selected circumstances. In brief, 8651 titles were identi- incidence of CDI and the significant economic burden of fied after excluding duplicates, and these abstracts were certain infection control measures, such as “deep cleaning” screened. Overall, 8014 articles were excluded and a total of hospital
Recommended publications
  • The Food Poisoning Toxins of Bacillus Cereus
    toxins Review The Food Poisoning Toxins of Bacillus cereus Richard Dietrich 1,†, Nadja Jessberger 1,*,†, Monika Ehling-Schulz 2 , Erwin Märtlbauer 1 and Per Einar Granum 3 1 Department of Veterinary Sciences, Faculty of Veterinary Medicine, Ludwig Maximilian University of Munich, Schönleutnerstr. 8, 85764 Oberschleißheim, Germany; [email protected] (R.D.); [email protected] (E.M.) 2 Department of Pathobiology, Functional Microbiology, Institute of Microbiology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria; [email protected] 3 Department of Food Safety and Infection Biology, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, P.O. Box 5003 NMBU, 1432 Ås, Norway; [email protected] * Correspondence: [email protected] † These authors have contributed equally to this work. Abstract: Bacillus cereus is a ubiquitous soil bacterium responsible for two types of food-associated gastrointestinal diseases. While the emetic type, a food intoxication, manifests in nausea and vomiting, food infections with enteropathogenic strains cause diarrhea and abdominal pain. Causative toxins are the cyclic dodecadepsipeptide cereulide, and the proteinaceous enterotoxins hemolysin BL (Hbl), nonhemolytic enterotoxin (Nhe) and cytotoxin K (CytK), respectively. This review covers the current knowledge on distribution and genetic organization of the toxin genes, as well as mechanisms of enterotoxin gene regulation and toxin secretion. In this context, the exceptionally high variability of toxin production between single strains is highlighted. In addition, the mode of action of the pore-forming enterotoxins and their effect on target cells is described in detail. The main focus of this review are the two tripartite enterotoxin complexes Hbl and Nhe, but the latest findings on cereulide and CytK are also presented, as well as methods for toxin detection, and the contribution of further putative virulence factors to the diarrheal disease.
    [Show full text]
  • The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio In
    microorganisms Review The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease Spase Stojanov 1,2, Aleš Berlec 1,2 and Borut Štrukelj 1,2,* 1 Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia; [email protected] (S.S.); [email protected] (A.B.) 2 Department of Biotechnology, Jožef Stefan Institute, SI-1000 Ljubljana, Slovenia * Correspondence: borut.strukelj@ffa.uni-lj.si Received: 16 September 2020; Accepted: 31 October 2020; Published: 1 November 2020 Abstract: The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD). Probiotics as live microorganisms can confer health benefits to the host when administered in adequate amounts. There is considerable evidence of their nutritional and immunosuppressive properties including reports that elucidate the association of probiotics with the F/B ratio, obesity, and IBD. Orally administered probiotics can contribute to the restoration of dysbiotic microbiota and to the prevention of obesity or IBD. However, as the effects of different probiotics on the F/B ratio differ, selecting the appropriate species or mixture is crucial. The most commonly tested probiotics for modifying the F/B ratio and treating obesity and IBD are from the genus Lactobacillus. In this paper, we review the effects of probiotics on the F/B ratio that lead to weight loss or immunosuppression.
    [Show full text]
  • Appendix III: OTU's Found to Be Differentially Abundant Between CD and Control Patients Via Metagenomeseq Analysis
    Appendix III: OTU's found to be differentially abundant between CD and control patients via metagenomeSeq analysis OTU Log2 (FC CD / FDR Adjusted Phylum Class Order Family Genus Species Number Control) p value 518372 Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium prausnitzii 2.16 5.69E-08 194497 Firmicutes Clostridia Clostridiales Ruminococcaceae NA NA 2.15 8.93E-06 175761 Firmicutes Clostridia Clostridiales Ruminococcaceae NA NA 5.74 1.99E-05 193709 Firmicutes Clostridia Clostridiales Ruminococcaceae NA NA 2.40 2.14E-05 4464079 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides NA 7.79 0.000123188 20421 Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus NA 1.19 0.00013719 3044876 Firmicutes Clostridia Clostridiales Lachnospiraceae [Ruminococcus] gnavus -4.32 0.000194983 184000 Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium prausnitzii 2.81 0.000306032 4392484 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides NA 5.53 0.000339948 528715 Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium prausnitzii 2.17 0.000722263 186707 Firmicutes Clostridia Clostridiales NA NA NA 2.28 0.001028539 193101 Firmicutes Clostridia Clostridiales Ruminococcaceae NA NA 1.90 0.001230738 339685 Firmicutes Clostridia Clostridiales Peptococcaceae Peptococcus NA 3.52 0.001382447 101237 Firmicutes Clostridia Clostridiales NA NA NA 2.64 0.001415109 347690 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira NA 3.18 0.00152075 2110315 Firmicutes Clostridia
    [Show full text]
  • Current Trends of Enterococci in Dairy Products: a Comprehensive Review of Their Multiple Roles
    foods Review Current Trends of Enterococci in Dairy Products: A Comprehensive Review of Their Multiple Roles Maria de Lurdes Enes Dapkevicius 1,2,* , Bruna Sgardioli 1,2 , Sandra P. A. Câmara 1,2, Patrícia Poeta 3,4 and Francisco Xavier Malcata 5,6,* 1 Faculty of Agricultural and Environmental Sciences, University of the Azores, 9700-042 Angra do Heroísmo, Portugal; [email protected] (B.S.); [email protected] (S.P.A.C.) 2 Institute of Agricultural and Environmental Research and Technology (IITAA), University of the Azores, 9700-042 Angra do Heroísmo, Portugal 3 Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5001-801 Vila Real, Portugal; [email protected] 4 Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, 2829-516 Lisboa, Portugal 5 LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, 420-465 Porto, Portugal 6 FEUP—Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal * Correspondence: [email protected] (M.d.L.E.D.); [email protected] (F.X.M.) Abstract: As a genus that has evolved for resistance against adverse environmental factors and that readily exchanges genetic elements, enterococci are well adapted to the cheese environment and may reach high numbers in artisanal cheeses. Their metabolites impact cheese flavor, texture, Citation: Dapkevicius, M.d.L.E.; and rheological properties, thus contributing to the development of its typical sensorial properties. Sgardioli, B.; Câmara, S.P.A.; Poeta, P.; Due to their antimicrobial activity, enterococci modulate the cheese microbiota, stimulate autoly- Malcata, F.X.
    [Show full text]
  • Sporulation Evolution and Specialization in Bacillus
    bioRxiv preprint doi: https://doi.org/10.1101/473793; this version posted March 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Research article From root to tips: sporulation evolution and specialization in Bacillus subtilis and the intestinal pathogen Clostridioides difficile Paula Ramos-Silva1*, Mónica Serrano2, Adriano O. Henriques2 1Instituto Gulbenkian de Ciência, Oeiras, Portugal 2Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal *Corresponding author: Present address: Naturalis Biodiversity Center, Marine Biodiversity, Leiden, The Netherlands Phone: 0031 717519283 Email: [email protected] (Paula Ramos-Silva) Running title: Sporulation from root to tips Keywords: sporulation, bacterial genome evolution, horizontal gene transfer, taxon- specific genes, Bacillus subtilis, Clostridioides difficile 1 bioRxiv preprint doi: https://doi.org/10.1101/473793; this version posted March 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Abstract Bacteria of the Firmicutes phylum are able to enter a developmental pathway that culminates with the formation of a highly resistant, dormant spore. Spores allow environmental persistence, dissemination and for pathogens, are infection vehicles. In both the model Bacillus subtilis, an aerobic species, and in the intestinal pathogen Clostridioides difficile, an obligate anaerobe, sporulation mobilizes hundreds of genes.
    [Show full text]
  • Clostridium Difficile Infection: How to Deal with the Problem DH INFORMATION RE ADER B OX
    Clostridium difficile infection: How to deal with the problem DH INFORMATION RE ADER B OX Policy Estates HR / Workforce Commissioning Management IM & T Planning / Finance Clinical Social Care / Partnership Working Document Purpose Best Practice Guidance Gateway Reference 9833 Title Clostridium difficile infection: How to deal with the problem Author DH and HPA Publication Date December 2008 Target Audience PCT CEs, NHS Trust CEs, SHA CEs, Care Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, PCT PEC Chairs, NHS Trust Board Chairs, Special HA CEs, Directors of Infection Prevention and Control, Infection Control Teams, Health Protection Units, Chief Pharmacists Circulation List Description This guidance outlines newer evidence and approaches to delivering good infection control and environmental hygiene. It updates the 1994 guidance and takes into account a national framework for clinical governance which did not exist in 1994. Cross Ref N/A Superseded Docs Clostridium difficile Infection Prevention and Management (1994) Action Required CEs to consider with DIPCs and other colleagues Timing N/A Contact Details Healthcare Associated Infection and Antimicrobial Resistance Department of Health Room 528, Wellington House 133-155 Waterloo Road London SE1 8UG For Recipient's Use Front cover image: Clostridium difficile attached to intestinal cells. Reproduced courtesy of Dr Jan Hobot, Cardiff University School of Medicine. Clostridium difficile infection: How to deal with the problem Contents Foreword 1 Scope and purpose 2 Introduction 3 Why did CDI increase? 4 Approach to compiling the guidance 6 What is new in this guidance? 7 Core Guidance Key recommendations 9 Grading of recommendations 11 Summary of healthcare recommendations 12 1.
    [Show full text]
  • Common Commensals
    Common Commensals Actinobacterium meyeri Aerococcus urinaeequi Arthrobacter nicotinovorans Actinomyces Aerococcus urinaehominis Arthrobacter nitroguajacolicus Actinomyces bernardiae Aerococcus viridans Arthrobacter oryzae Actinomyces bovis Alpha‐hemolytic Streptococcus, not S pneumoniae Arthrobacter oxydans Actinomyces cardiffensis Arachnia propionica Arthrobacter pascens Actinomyces dentalis Arcanobacterium Arthrobacter polychromogenes Actinomyces dentocariosus Arcanobacterium bernardiae Arthrobacter protophormiae Actinomyces DO8 Arcanobacterium haemolyticum Arthrobacter psychrolactophilus Actinomyces europaeus Arcanobacterium pluranimalium Arthrobacter psychrophenolicus Actinomyces funkei Arcanobacterium pyogenes Arthrobacter ramosus Actinomyces georgiae Arthrobacter Arthrobacter rhombi Actinomyces gerencseriae Arthrobacter agilis Arthrobacter roseus Actinomyces gerenseriae Arthrobacter albus Arthrobacter russicus Actinomyces graevenitzii Arthrobacter arilaitensis Arthrobacter scleromae Actinomyces hongkongensis Arthrobacter astrocyaneus Arthrobacter sulfonivorans Actinomyces israelii Arthrobacter atrocyaneus Arthrobacter sulfureus Actinomyces israelii serotype II Arthrobacter aurescens Arthrobacter uratoxydans Actinomyces meyeri Arthrobacter bergerei Arthrobacter ureafaciens Actinomyces naeslundii Arthrobacter chlorophenolicus Arthrobacter variabilis Actinomyces nasicola Arthrobacter citreus Arthrobacter viscosus Actinomyces neuii Arthrobacter creatinolyticus Arthrobacter woluwensis Actinomyces odontolyticus Arthrobacter crystallopoietes
    [Show full text]
  • Cwp22, a Novel Peptidoglycan Cross-Linking Enzyme, Plays Pleiotropic Roles in Clostridioides Difficile
    Environmental Microbiology (2019) 21(8), 3076–3090 doi:10.1111/1462-2920.14706 Cwp22, a novel peptidoglycan cross-linking enzyme, plays pleiotropic roles in Clostridioides difficile Duolong Zhu ,1 Jessica Bullock,1 Yongqun He2 and Introduction Xingmin Sun1* Clostridioides difficile (formerly Clostridium difficile) (Lawson 1Department of Molecular Medicine, Morsani College of et al., 2016; Oren and Garrity, 2018) is a Gram-positive, Medicine, University of South Florida, Tampa, FL, USA. spore-forming, toxin-producing, anaerobic bacterium that 2Department of Microbiology and Immunology, and has established itself as a leading cause of nosocomial Center for Computational Medicine and Bioinformatics, antibiotic-associated diarrhoea in developed countries Unit for Laboratory Animal Medicine, University of (Sebaihia et al., 2006). Symptoms of C. difficile infection Michigan Medical School, Ann Arbor, MI, USA. (CDI) range from mild diarrhoea, intestinal inflammation to pseudomembranous colitis (Lessa et al., 2012). Recently, Summary morbidity and mortality rates of CDI have been increasing Clostridioides difficile is a Gram-positive, spore-forming, steadily, causing over 500,000 infections per year in the – toxin-producing anaerobe pathogen, and can induce United States alone with an estimated cost of $1 3 billion nosocomial antibiotic-associated intestinal disease. (Dubberke and Olsen, 2012; Lessa et al., 2015). fi While production of toxin A (TcdA) and toxin B (TcdB) C. dif cile has a number of virulence factors. Among contribute to the main pathogenesis of C. difficile, them are two large potent exotoxins, toxin A (TcdA) and adhesion and colonization of C. difficile in the host gut toxin B (TcdB) that are recognized as the major virulence fi are prerequisites for disease onset.
    [Show full text]
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    Methicillin-Resistant Staphylococcus Aureus (MRSA) Over the past several decades, the incidence of resistant gram-positive organisms has risen in the United States. MRSA strains, first identified in the 1960s in England, were first observed in the U.S. in the mid 1980s.1 Resistance quickly developed, increasing from 2.4% in 1979 to 29% in 1991.2 The current prevalence for MRSA in hospitals and other facilities ranges from <10% to 65%. In 1999, MRSA accounted for more than 50% of all Staphylococcus aureus isolates within U.S. intensive care units.3, 4 The past years, however, outbreaks of MRSA have also been seen in the community setting, particularly among preschool-age children, some of whom have attended day-care centers.5, 6, 7 MRSA does not appear to be more virulent than methicillin-sensitive Staphylococcus aureus, but certainly poses a greater treatment challenge. MRSA also has been associated with higher hospital costs and mortality.8 Within a decade of its development, methicillin resistance to Staphylococcus aureus emerged.9 MRSA strains generally are now resistant to other antimicrobial classes including aminoglycosides, beta-lactams, carbapenems, cephalosporins, fluoroquinolones and macrolides.10,11 Most of the resistance was secondary to production of beta-lactamase enzymes or intrinsic resistance with alterations in penicillin-binding proteins. Staphylococcus aureus is the most frequent cause of nosocomial pneumonia and surgical- wound infections and the second most common cause of nosocomial bloodstream infections.12 Long-term care facilities (LTCFs) have developed rates of MRSA ranging from 25%-35%. MRSA rates may be higher in LTCFs if they are associated with hospitals that have higher rates.13 Transmission of MRSA generally occurs through direct or indirect contact with a reservoir.
    [Show full text]
  • Clostridioides Difficileinfections
    bioMérieux In vitro diagnostics serving CLOSTRIDIOIDES public health DIFFICILE INFECTIONS A major player in in vitro diagnostics for more than 50 years, From Diagnosis to bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Outbreak Management Our diagnostic solutions bring high medical value to healthcare professionals, providing them with the most relevant and reliable information, as quickly as possible, to support treatment decisions and better patient care. bioMérieux’s mission entails a commitment to support medical education, by promoting access to diagnostic knowledge for as many people as possible. Focusing on the medical value of diagnostics, our collection of educational booklets aims to raise awareness of the essential role that diagnostic test results play in healthcare decisions. Other educational booklets are available. Consult your local bioMérieux representative. The information in this booklet is for educational purposes only and is not intended to be exhaustive. It is not intended to be a substitute for professional medical advice. Always consult a medical director, physician, or other qualified health provider regarding processes and/or protocols for diagnosis and treatment of a medical condition. bioMérieux assumes no responsibility or liability for any diagnosis established or treatment prescribed by the physician. bioMérieux, Inc. • 100 Rodolphe Street • Durham, NC 27712 • USA • Tel: (800) 682 2666 • Fax: (800) 968 9494 © 2019 bioMérieux, Inc. • BIOMERIEUX and the BIOMERIEUX logo, are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies. companies. its or one of subsidiaries, its or one of bioMérieux, belonging to trademarks registered pending and/or used are logo, and the BIOMERIEUX • BIOMERIEUX Inc.
    [Show full text]
  • Use of the Diagnostic Bacteriology Laboratory: a Practical Review for the Clinician
    148 Postgrad Med J 2001;77:148–156 REVIEWS Postgrad Med J: first published as 10.1136/pmj.77.905.148 on 1 March 2001. Downloaded from Use of the diagnostic bacteriology laboratory: a practical review for the clinician W J Steinbach, A K Shetty Lucile Salter Packard Children’s Hospital at EVective utilisation and understanding of the Stanford, Stanford Box 1: Gram stain technique University School of clinical bacteriology laboratory can greatly aid Medicine, 725 Welch in the diagnosis of infectious diseases. Al- (1) Air dry specimen and fix with Road, Palo Alto, though described more than a century ago, the methanol or heat. California, USA 94304, Gram stain remains the most frequently used (2) Add crystal violet stain. USA rapid diagnostic test, and in conjunction with W J Steinbach various biochemical tests is the cornerstone of (3) Rinse with water to wash unbound A K Shetty the clinical laboratory. First described by Dan- dye, add mordant (for example, iodine: 12 potassium iodide). Correspondence to: ish pathologist Christian Gram in 1884 and Dr Steinbach later slightly modified, the Gram stain easily (4) After waiting 30–60 seconds, rinse with [email protected] divides bacteria into two groups, Gram positive water. Submitted 27 March 2000 and Gram negative, on the basis of their cell (5) Add decolorising solvent (ethanol or Accepted 5 June 2000 wall and cell membrane permeability to acetone) to remove unbound dye. Growth on artificial medium Obligate intracellular (6) Counterstain with safranin. Chlamydia Legionella Gram positive bacteria stain blue Coxiella Ehrlichia Rickettsia (retained crystal violet).
    [Show full text]
  • Complete Genome Sequences of Two Enterococcus Faecium Strains and Comparative Genomic Analysis
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2019-2028, 2020 Complete genome sequences of two Enterococcus faecium strains and comparative genomic analysis YONG‑QI GAN, TAO ZHANG, YONG‑QIANG GAN, ZHUANG ZHAO and BIN ZHU Guangxi Institute for Food and Drug Control, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China Received December 1, 2018; Accepted August 12, 2019 DOI: 10.3892/etm.2020.8447 Abstract. Enterococci are used for improvement of the intes- environment when treating bacterial diarrhea (3). There are tinal environment and have clinical benefits. Enterococcus two main advantages to Enterococcus that make it the most faecalis and Enterococcus faecium have similar morpholo- popular edible probiotic in animals and humans: i) In the gies, leading to confusion between the two species. In order gastrointestinal (GI) tract, Enterococcus competes with patho- to identify the National Institute for Food and Drug Control gens and thus decreases their virulence (2); ii) Enterococcus (strain 140623) and Shin Biofermin S (strain SBS-1, one of resists acid stress and cannot be digested by GI‑secreted diges- the cocci), which are widely used clinically, the present study tive juice (4). E. faecalis and E. faecium are used as digestive sequenced and analyzed these two strains. The biochemical agents for the treatment of diarrhea caused by flatulence characteristics, gas chromatography and mass spectrometry and indigestion (2). However, these two bacteria are difficult results of 140623 and SBS-1 revealed that the two strains were to distinguish morphologically. Species identification and more similar to E. faecium than E. faecalis. The genomes of genome characterization of these strains may elucidate thera- 140623 and SBS-1 contained 2,812,926 bp and 2,797,745 bp, peutic strategies for bacterial infection and probiotic treatment respectively, based on Illumina HiSeq 2000 sequencing.
    [Show full text]